Any current/future new fundraising through debt or equity?

The company has already reduced debt by Rs. 240 crores using IPO proceeds. There will be new borrowing under the interest subvention scheme to fund the grain-based ethanol facility (dual-feed corn/grain-based distillation plant). Targeted borrowing for this project is around Rs. 119 crores at approximately 5.4% interest. The company is actively investing in debottlenecking chemical capacities and constructing a biobutanol plant, indicating ongoing capital expenditure plans. No specific mention of upcoming equity fundraising beyond the IPO. Overall, future funding will be a combination of new b

Any current/future capex/capital investment/strategic investment?

Investment in a new dual-feed 200 KL/day corn/grain-based ethanol facility targeted for commissioning in Q4 FY26 (H2 FY26) to enhance ethanol production capacity and mitigate climate and policy risk. Licensing of technology from Catalyxx Incorporated for biobutanol and higher alcohol production with a first phase plant capacity of 15,000 tons/year; commissioning planned in Q2 FY27. Debottlenecking of bio-based specialty chemical capacities, including recent expansion of 1,3 butylene glycol capacity from 120 to 200 tons/month, with further debottlenecking planned in coming quarters. Continued t

Future growth expectations in sales/revenue/volumes?

Ethanol business expected to grow significantly in FY26 and FY27 due to investments in grain-based distillation and government ethanol blending program participation. Bio-based chemical segment to expand with debottlenecking and new biobutanol technology licensing, targeting commissioning in Q2 FY27. Sugar segment anticipated to remain largely static in revenue contribution. Focus on multi-feedstock ethanol production (sugarcane and grain/corn) to mitigate climate and policy risks. Expansion in specialty bio-based chemicals such as 1,3-butylene glycol and ethyl vinyl ether expected due

Future growth expectations in earnings/operating earnings/profits/EPS?

Ethanol business expected to grow significantly in FY26 and FY27 with new dual-feed corn/grain-based facility commissioning in H2 FY26, enhancing capacity and mitigating climate risk. Bio-based chemicals segment poised for growth due to debottlenecked capacities (e.g., 1,3 butylene glycol expansion) and licensing of biobutanol technology, with biobutanol facility planned for Q2 FY27. Sugar segment seen as largely static, with growth primarily driven by ethanol and bio-based chemicals. Debt reduced by Rs. 240 crores using IPO proceeds, lowering interest expenses and improving cash flow, a

Godavari Bioref.Q3 FY25Diversified FMCG

Godavari Bioref. Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹227P/E: 41.7Market Cap: ₹1.2K CrSector: Diversified FMCG

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Ethanol business expected to grow significantly in FY26 and FY27 due to investments in grain-based distillation and government ethanol blending program participation.
Bio-based chemical segment to expand with debottlenecking and new biobutanol technology licensing, targeting commissioning in Q2 FY27.
Sugar segment anticipated to remain largely static in revenue contribution.
Focus on multi-feedstock ethanol production (sugarcane and grain/corn) to mitigate climate and policy risks.
Expansion in specialty bio-based chemicals such as 1,3-butylene glycol and ethyl vinyl ether expected due to strong demand in fragrances, skincare, coatings, and adhesives.
Revenue in biochemical segment poised to grow from increased volume and new product launches, with potential Rs. 250 crore revenue from biobutanol facility at full capacity by second year.
Export growth through co-creation of bio-based chemical solutions for Indian and global markets.

Margin guidance

Category 3

Ethanol business expected to grow significantly in FY26 and FY27 with new dual-feed corn/grain-based facility commissioning in H2 FY26, enhancing capacity and mitigating climate risk.
Bio-based chemicals segment poised for growth due to debottlenecked capacities (e.g., 1,3 butylene glycol expansion) and licensing of biobutanol technology, with biobutanol facility planned for Q2 FY27.
Sugar segment seen as largely static, with growth primarily driven by ethanol and bio-based chemicals.
Debt reduced by Rs. 240 crores using IPO proceeds, lowering interest expenses and improving cash flow, aiding operational profitability.
Exclusive manufacturing license (Catalyxx) expected to generate Rs. 250 crore revenue at full capacity in the second year, supporting earnings growth.
Overall, transitioning toward higher-margin bio-based chemicals and ethanol businesses, expected to strengthen EBITDA and PAT in coming years.

See what Godavari Bioref. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company has already reduced debt by Rs. 240 crores using IPO proceeds.
There will be new borrowing under the interest subvention scheme to fund the grain-based ethanol facility (dual-feed corn/grain-based distillation plant).
Targeted borrowing for this project is around Rs. 119 crores at approximately 5.4% interest.
The company is actively investing in debottlenecking chemical capacities and constructing a biobutanol plant, indicating ongoing capital expenditure plans.
No specific mention of upcoming equity fundraising beyond the IPO.
Overall, future funding will be a combination of new borrowings for ethanol programs, normal principal repayments, and working capital needs.

Order book

The transcript provided does not explicitly mention details about the current, expected order book, or pending orders for Godavari Biorefineries Limited. However, the following relevant points can be inferred related to business outlook and growth initiatives: - The company has signed an exclusive India license agreement with Catalyxx Incorporated to convert ethanol into biobutanol and higher alcohols, aiming to produce 15,000 metric tons initially with plans to expand to 30,000 metric tons (Page 4 & 9). - They have already contracted some export quota (5,400 tons) of sugar (Page 12), with sales ongoing. - Focus on expanding bio-based chemical capacity through debottlenecking and new projects indicates strong demand and ongoing production expansion (Page 3 & 7). - Discussions reflect ongoing customer engagement globally for biobutanol (Page 9). - The new dual-feed corn/grain ethanol plant to be commissioned indicates growth in product capacity (Page 4 & 8). No precise numeric order book data is disclosed.

See what Godavari Bioref. management said on order book — free account, 30 seconds.

Capex plans

Yes

Investment in a new dual-feed 200 KL/day corn/grain-based ethanol facility targeted for commissioning in Q4 FY26 (H2 FY26) to enhance ethanol production capacity and mitigate climate and policy risk.
Licensing of technology from Catalyxx Incorporated for biobutanol and higher alcohol production with a first phase plant capacity of 15,000 tons/year; commissioning planned in Q2 FY27.
Debottlenecking of bio-based specialty chemical capacities, including recent expansion of 1,3 butylene glycol capacity from 120 to 200 tons/month, with further debottlenecking planned in coming quarters.
Continued transition and investment focus on ethanol blending program and bio-based chemicals as core growth strategies.
Capital investments expected to improve operational efficiencies and support sustainable growth.
Total gross block as of now is Rs. 1,245 crores, with further capitalization planned especially in ethanol and bio-based chemicals segments.

Track Godavari Bioref. — get its next earnings analysis in your feed

How does Godavari Bioref. rank vs peers in Diversified FMCG?

Pro feature

ThisGodavari Bioref.

Rev 2Mar 3

See where Godavari Bioref. sits in Diversified FMCGSee which companies these are, and every other name in the sector.Open rankings

How does Godavari Bioref. rank in Diversified FMCG?

Compare Godavari Bioref. against every Diversified FMCG company (Q3 FY25) on revenue, margins and earnings-call signals.

View Diversified FMCG leaderboard →

What Godavari Bioref.'s management said in earlier quarters

Others in Diversified FMCG this season

ITC Ltd (Q2 FY25)
1,457 crore (versus Rs. Key concall takeaways from ITC Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
ITC Ltd (Q3 FY25)
8,344 crore. Key concall takeaways from ITC Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
ITC Ltd (Q4 FY25)
Q4 FY25 Gross Revenue: ₹18,266 crore, up 9.2% YoY (Page 42) . Key concall takeaways from ITC Ltd's Q4 FY25 earnings call — and how it ranks against sector…
ITC Ltd (Q1 FY26)
20,911 crore, up 19.8% YoY (Page 41) . Key concall takeaways from ITC Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Hind. Unilever vs ITC Ltd vs Hindustan Foods

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →